Clinical Trials Sponsored by Pronova BioPharma

Total 1503 results

Pronova BioPharma

Terminated

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Dyslipidemia

United States
Pronova BioPharma

Completed

PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study

Healthy

United Kingdom
Pronova BioPharma

Completed

Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Healthy

United Kingdom
Pronova BioPharma

Completed

Bioavailability of Omega-3 Food Supplements in Healthy Subjects

Healthy

United Kingdom
Pronova BioPharma

Completed

[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study

Healthy

United Kingdom
Pronova BioPharma

Completed

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Dyslipidemia

United States
Pronova BioPharma

Completed

Bioavailability of Omega-3 Food Supplement in Healthy Subjects

Biological Availability

United Kingdom
Pronova BioPharma

Completed

Omacor and Placebo in Carotid Plaque Stability

Cardiovascular Disease

United Kingdom
Nordlandssykehuset HF
Pronova BioPharma

Completed

Effect of Omega-3 Fatty Acid on Endothelial Function

Familial Hypercholesterolemia

Norway
Northumbria University
Pronova BioPharma

Completed

26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults

Neurovascular Coupling

United Kingdom
Northumbria University
Pronova BioPharma

Completed

The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood

Cognitive Function

United Kingdom
Northumbria University
Pronova BioPharma

Completed

Plasma Diurnal Variation in and Absorption of EPA and DHA

Lipid Absorption and Metabolism

United Kingdom
Penn State University
Pronova BioPharma

Completed

Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation (PRONOVA)

Inflammatory Responses

United States
Pronova BioPharma
Aalborg University Hospital

Completed

Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment

Ischemic Heart Disease | Human Immunodeficiency Virus

Denmark
Kuhnil Pharmaceutical Co., Ltd.
Pronova BioPharma ASA

Completed

Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of
Pronova BioPharma
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

Non Alcoholic Fatty Liver

United States
National Center for Complementary and Integrative...
Pronova BioPharma

Completed

Omega-3 Fatty Acids in Bipolar Disorder

Bipolar Disorder

United States
Stiftung Institut fuer Herzinfarktforschung
Pronova BioPharma; Trommsdorff GmbH & Co. KG

Completed

OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction (OMEGA)

Myocardial Infarction

Germany
Pronova BioPharma
Danish Heart Foundation; The Danish Kidney Association; North Jutland County

Completed

Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis

Kidney Failure, Chronic

Denmark
Helse Stavanger HF
University of Oslo; University of Bergen; Pronova BioPharma; Pharmacia and Upjohn

Completed

Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction (OFAMI)

Myocardial Infarction | Coronary Disease

Norway
Oslo University Hospital
Aarhus University Hospital; Aalborg University Hospital; South-Eastern Norway... and other collaborators

Completed

The Effects of Omega-3 Fatty Acids in Renal Transplantation (ORENTRA)

Disorder Related to Renal Transplantation

Norway
Bronovo Hospital

Completed

Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery

Hip Fracture | Post-Operative Delirium

Netherlands
Aronora, Inc.

Completed

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Thrombosis

United States
Sonova AG
Sonova Canada Inc.

Terminated

Compression Headphone Study

Hearing Loss

Canada
Sonova AG
Sonova Canada Inc.

Completed

Validation of Novel BTE and SP Hearing Aid Models

Hearing Loss

Canada
Aronora, Inc.

Completed

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
BaroNova, Inc.

Completed

ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss

Obesity

United States
Aronora, Inc.

Completed

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Thrombosis

United States
BaroNova, Inc.

Completed

A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects

Obesity

Australia
Sonova AG
Sonova Canada Inc.

Completed

Speech Locator In-car Performance Evaluation

Hearing Loss

Canada
Sonova AG
Sonova Canada Inc.

Completed

Clinical Study of Released Unitron RIC and BTE Hearing Aid Models

Hearing Loss

Canada
Lantu Biopharma

Not yet recruiting

An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Beta-Thalassemia
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Estonia, Canada, France, Chile
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Kinnate Biopharma

Active, not recruiting

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Intrahepatic Cholangiocarcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Korea, Republic of, Taiwan, China, Denmark, Spain
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
DS Biopharma

Completed

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Atopic Dermatitis

United States, South Africa
Theravance Biopharma

Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (SEQUOIA)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Israel, Hungary, Portugal, Australia, Canada, Germany, Russian Federation, Estonia, France, Italy, United Kingdom, Denmark, Poland, New Zealand, Austria, Bulgaria, Ukraine
United BioPharma

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic

Taiwan
Theravance Biopharma

Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Asthma

United Kingdom
Theravance Biopharma

Completed

Phase 2 Study of TD-9855 to Treat Fibromyalgia

Fibromyalgia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Healthy

United States

Clinical Trials Sponsored by Pronova BioPharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations